Display options
Cite
Goldin LR, Björkholm M, Kristinsson SY, et al. Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms. Genome Med. 2009;1(5):55doi: 10.1186/gm55.
Goldin, L. R., Björkholm, M., Kristinsson, S. Y., Samuelsson, J., & Landgren, O. (2009). Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms. Genome medicine, 1(5), 55. https://doi.org/10.1186/gm55
Goldin, Lynn R, et al. "Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms." Genome medicine vol. 1,5 (2009): 55. doi: https://doi.org/10.1186/gm55
Goldin LR, Björkholm M, Kristinsson SY, Samuelsson J, Landgren O. Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms. Genome Med. 2009 May 29;1(5):55. doi: 10.1186/gm55. PMID: 19490586; PMCID: PMC2689447.
Copy Download .nbib Format: NLM
Share it on

Genome Med. 2009 May 29;1(5):55. doi: 10.1186/gm55.

Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms.

Genome medicine

Lynn R Goldin, Magnus Björkholm, Sigurdur Y Kristinsson, Jan Samuelsson, Ola Landgren

Affiliations

  1. Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-7236, USA.

PMID: 19490586 PMCID: PMC2689447 DOI: 10.1186/gm55

Abstract

Myeloproliferative neoplasms (MPNs) are a group of closely related stem-cell-derived clonal proliferative diseases. Most cases are sporadic but first-degree relatives of MPN patients have a five- to seven-fold increased risk for developing an MPN. The tumors of most patients carry a mutation in the Janus kinase 2 gene (JAK2(V617F)). Recently, three groups have described a strong association of JAK2 germline polymorphisms with MPN in patients positive for JAK2(V617F). The somatic mutation occurs primarily on one particular germline JAK2 haplotype, which may account for as much as 50% of the risk to first-degree relatives. This finding provides new directions for unraveling the pathogenesis of MPN.

References

  1. Leukemia. 2008 Jan;22(1):14-22 - PubMed
  2. Leuk Res. 2008 Oct;32(10):1489-90 - PubMed
  3. Surg Oncol Clin N Am. 2009 Jan;18(1):1-17, vii - PubMed
  4. Arch Pathol Lab Med. 2006 Aug;130(8):1144-50 - PubMed
  5. Nat Genet. 2009 Apr;41(4):450-4 - PubMed
  6. Hematol Oncol. 2008 Sep;26(3):131-8 - PubMed
  7. Blood. 2006 Jul 1;108(1):346-52 - PubMed
  8. Cell Cycle. 2007 Mar 1;6(5):550-66 - PubMed
  9. Am J Med. 2004 Nov 15;117(10):755-61 - PubMed
  10. Nat Genet. 2009 Apr;41(4):455-9 - PubMed
  11. Blood. 2008 Sep 15;112(6):2587-8; author reply 2588-9 - PubMed
  12. Nat Genet. 2009 Apr;41(4):446-9 - PubMed
  13. Blood. 2009 Feb 26;113(9):2022-7 - PubMed
  14. Blood. 2008 Sep 15;112(6):2199-204 - PubMed
  15. Semin Thromb Hemost. 2007 Jun;33(4):313-20 - PubMed
  16. Eur J Haematol. 2008 May;80(5):386-90 - PubMed
  17. Hematology Am Soc Hematol Educ Program. 2007;:346-54 - PubMed

Publication Types